These results indicated that cardiomyocyte ADAM17 deficiency exerts a cardioprotective effect on doxorubicin-induced cardiomyopathy without affecting the anti-tumor effect of doxorubicin. This evidence concerns the gene ADAM17 and cardiomyopathy.